Abstract: An organic light-emitting device and a flat panel display device, the organic-light emitting device including an anode; a cathode; and an organic layer therebetween including an emission layer, a hole transport region between the anode and the emission layer, the hole transport region including at least one of a hole injection layer, a hole transport layer, and an electron blocking layer, an electron transport region between the emission layer and the cathode, the electron transport region including at least one of a hole blocking layer, an electron transport layer, and an electron injection layer, and a buffer layer between the emission layer and the electron transport region, wherein the buffer layer includes a biscarbazole-based derivative and triphenylene-based derivative, and a triplet energy (ET1) of the biscarbazole-based derivative or the triphenylene-based derivative and a triplet energy (ET2) of a dopant of the emission layer satisfy the following relationship: ET1>ET2.

Abstract: The present invention relates to a main magnetic component applicable to a core module of an electric vehicle. A composite magnetic component according to one embodiment of the present invention comprises: a transformer that converts power on an input side to transmit same to an output side, and has a first core and a first coil disposed in the first core; a ZVS inductor that refluxes a residual current to the input side without FET operation loss, and has a second core and a second coil disposed within the second core; an output inductor that removes the ripple of a current on the output side, and has a third core and a third coil disposed in the third core; and an EMI inductor that reduces electric noise of the current on the output side, and has a fourth core and a fourth coil disposed in the fourth core. Here, the second core, the third core, and the fourth core are made of different materials, and the first core and the second core are made of the same material.

Abstract: The present invention relates to a novel benzotriazole derivative compound, a tautomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a stereoisomer thereof, which are related to a compound for inhibiting ENPP1, a composition for inhibiting ENPP1, and a method for inhibiting ENPP1.

Abstract: A method of activating a secondary battery includes an operation of deriving a reduction reaction voltage according to an electrolyte additive, a pre-charging operation of pre-charging the secondary battery into which an electrolyte containing the electrolyte additive is injected, and a pre-aging operation of wetting an electrode assembly accommodated in the secondary battery with the injected electrolyte and aging the electrode assembly. A charging termination voltage in the pre-charging operation is less than the reduction reaction voltage.

Abstract: The present invention relates to a compound capable of lowering the flammability of a non-aqueous electrolyte when included in the non-aqueous electrolyte and improving the life properties of a battery by forming an electrode-electrolyte interface which is stable at high temperatures and low in resistance, and relates to a compound represented by Formula I descried herein, a non-aqueous electrolyte solution and a lithium secondary battery both including the compound, n, m, Ak, and X are described herein.

Abstract: The present invention relates to a modified conjugated diene-based polymer having excellent rolling resistance and improved processability, a method for preparing the same and a rubber composition including the same, and provides a modified conjugated diene-based polymer which includes a repeating unit derived from a conjugated diene-based monomer, and a functional group derived from a modifier, and satisfies conditions (i) to (vii), a method for preparing the same and a rubber composition including the same.

Abstract: A display device includes a thin-film transistor, a source/drain electrode and an auxiliary electrode including a first conductive layer and a second conductive layer disposed on the first conductive layer, a via insulating layer having a first opening exposing the auxiliary electrode, a capping layer covering a portion of the auxiliary electrode and a light emitting material layer and a common electrode layer sequentially stacked on the via insulating layer and the capping layer, wherein the source/drain electrode is electrically connected to the thin-film transistor through a contact hole penetrating the interlayer insulating layer, the auxiliary electrode has an undercut, and the capping layer includes a first capping layer covering side surfaces of the first conductive layer of the auxiliary electrode and a second capping layer separated from the first capping layer and disposed on the second conductive layer of the auxiliary electrode.

Abstract: A display device may include a first electrode, a second electrode, an emission layer, an intervening layer, and a first encapsulation layer. The second electrode may overlap the first electrode. The emission layer may be disposed between the first electrode and the second electrode, may overlap the first electrode, and may include a light emitting material. The intervening layer may directly contact the second electrode, may be spaced from each of the first electrode and the emission layer, and may include a fluorine compound. A first section of the first encapsulation layer may overlap the emission layer. The intervening layer may be positioned between the second electrode and a second section of the first encapsulation layer.

Abstract: Disclosed are a fusion protein comprising a thyrotropin receptor (TSHR) fragment and the use thereof. More specifically, disclosed are a fusion protein comprising a TSHR fragment comprising an extracellular domain of a wild-type TSHR and having a substitution of an amino acid at specific position and an immunoglobulin Fc region or a carboxy-terminal cap (C-CAP), and the use thereof. The fusion protein has improved pharmaceutical efficacy, in-vivo persistence and protein stability and a pharmaceutical composition containing the fusion protein as an active ingredient is useful as a therapeutic agent or diagnostic reagent for the alleviation of Graves' disease and Graves' ophthalmopathy.

Abstract: The present invention relates to: a cell culture medium for culturing extracellular vesicles at high concentration, the medium comprising lactoferrin; a method for preparing a conditioned medium containing a high concentration of extracellular vesicles, the method comprising culturing cells in the cell culture medium; and use of lactoferrin in preparing a conditioned medium containing a high concentration of extracellular vesicles.

Abstract: Disclosed are a fusion protein comprising a thyrotropin receptor (TSHR) fragment and the use thereof. More specifically, disclosed are a fusion protein comprising a TSHR fragment comprising an extracellular domain of a wild-type TSHR and having a substitution of an amino acid at specific position and an immunoglobulin Fc region or a carboxy-terminal cap (C-CAP), and the use thereof. The fusion protein has improved pharmaceutical efficacy, in-vivo persistence and protein stability and a pharmaceutical composition containing the fusion protein as an active ingredient is useful as a therapeutic agent or diagnostic reagent for the alleviation of Graves' disease and Graves' ophthalmopathy.

Abstract: Provided are a composition for improving skin wrinkles or inflammation, the composition including substance P as an active ingredient, more particularly, novel use of a composition including substance P which promotes collagen synthesis, inhibits collagenase production, and performs anti-inflammatory responses to improve skin wrinkles or inflammation, and a cosmetic composition for improving skin wrinkles or inflammation including the composition. The composition of the present invention, which includes substance P, exhibits higher effects of improving skin wrinkle or inflammation than substance P alone, due to a synergistic effect of an antioxidant, a surfactant, and a thickener which are added for stability of substance P, together with basic characteristics of substance P which is known to have effects of improving skin wrinkles or inflammation. Accordingly, the composition of the present invention may be usefully applied to a cosmetic composition for improving skin wrinkles or inflammation.

Abstract: Provided are a pharmaceutical composition for wound healing including a surfactant, an antioxidant, a thickener, and SP, a method of treating a wound including administering the pharmaceutical composition to a subject, and a quasi-drug composition for wound healing including a surfactant, an antioxidant, a thickener, and substance. The pharmaceutical composition of the present invention reduces a wound size, generates new blood vessels, shows dermal and epidermal regeneration effects, matures granulation tissues, and synthesizes collagen, and thus may be used for wound healing.

Abstract: The present invention relates to an artificial cartilage containing mesenchymal stem cell (MSC)-like dedifferentiated cells obtained by passage culturing costal chondrocytes, and a preparation process thereof.

Abstract: A photosensitive resin composition includes (A) a binder resin including an epoxy resin; (B) a photopolymerizable monomer; (C) a photopolymerization initiator; (D) a colorant including a dye represented by the following Chemical Formula 1, wherein in the above Chemical Formula 1, each substituent is the same as defined in the detailed description; and (E) a solvent.

Abstract: Provided are a pharmaceutical composition for wound healing including a surfactant, an antioxidant, a thickener, and SP, a method of treating a wound including administering the pharmaceutical composition to a subject, and a quasi-drug composition for wound healing including a surfactant, an antioxidant, a thickener, and substance. The pharmaceutical composition of the present invention reduces a wound size, generates new blood vessels, shows dermal and epidermal regeneration effects, matures granulation tissues, and synthesizes collagen, and thus may be used for wound healing.

Abstract: The present invention relates to a preparation method for a therapeutic agent of a bead-type chondrocyte and, more specifically, to: a preparation method for a therapeutic agent of a bead-type chondrocyte without a support, comprising the steps of: a) dispensing chondrocytes and/or cells having chondrogenic differentiation capability in a 96-well deep well plate having a V-shaped bottom; b) centrifuging the plate; c) three-dimensionally culturing the plate in an incubator; and d) recovering pellets from each well, thereby being capable of easily and stably preparing cartilage tissues of a uniform quality, in large quantities; and a therapeutic agent of a bead-type chondrocyte without a support, prepared by the method, having effectiveness to repair damage by simply being implanted into cartilage damage by injection.

Abstract: The present invention relates to a composition for preventing or treating cancer comprising Wnt decoy receptor. The composition of the present invention or the expression product thereof inhibits cancer generation, growth, proliferation and metastasis, and induces apoptosis of cancer cells, by binding to Wnt ligand and blocking ligand-receptor interactions, therefore may be effectively used as an anti-cancer agent.

Abstract: The present invention relates to a composition for preventing or treating cancer comprising Wnt decoy receptor. The composition of the present invention or the expression product thereof inhibits cancer generation, growth, proliferation and metastasis, and induces apoptosis of cancer cells, by binding to Wnt ligand and blocking ligand-receptor interactions, therefore may be effectively used as an anti-cancer agent.

Abstract: The present invention relates to an artificial cartilage containing mesenchymal stem cell (MSC)-like dedifferentiated cells obtained by passage culturing costal chondrocytes, and a preparation process thereof.